Skip to main content

Table 1 BCMA-targeted CAR T cell clinical trials in multiple myeloma

From: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism

Signal domain ORR Efficacy Side effect Conditioning Registration code
CR sCR PR VGPR CRS CRES
CD28 20% 1 1 Gr3/4, 38% (high dose) Gr3/4, 19% (high dose) CP/Flu NCT02215967
CD28 87% Gr3, 14% CP/Flu ChiCTR-OPC-16009113
4-1BB 85% 3 12 4 9 Gr1/2, 70% Gr1/2, 39%
Gr4, 3%
CP/Flu NCT02658929
4-1BB 86% 1 2 3 Gr1/2, 50%
Gr3, 12.5%
Gr4, 12.5% CP NCT03274219
4-1BB 88% 39 8 3 Gr1/2, 83%
Gr3/4, 7%
Gr1, 1.8% CP/Flu NCT03090659
4-1BB 88.2% 13 2 Mild, 10
Severe, 6
Very severe, 1
CP/Flu ChiCTR-ONH-17012285
4-1BB 89% 1 1 5 1 Gr2, 1 CP/Flu NCT03288493
4-1BB 100% 1 2 1 2 Gr1/2, 75% Gr1/2, 38% CP/Flu NCT03430011
4-1BB 100% 3 4 6 Gr1–3, 1 none CP/Flu NCT03915184
4-1BB 64% Gr1/2, 40%
Gr3, 20%
Gr2, 10% CP/Flu NCT03070327
4-1BB 100% 4 4 1 Mild
DLT
CP/Flu ChiCTR1800018137
4-1BB 79% 3 4 2 Mild CP/Flu NCT03093168
4-1BB 48% 1 1 5 5 Gr3/4, 32% Gr3/4, 12% CP or none NCT02546167
4-1BB 100% 1 3 Under Gr3 CP/Flu NCT03661554
4-1BB 95% 3 9 3 5 Gr1–2, 86%
Gr3, 5%
CP/Flu ChiCTR-OIC-17011272
OX40, CD28 80% 1 2 1 Mild Bu-CP + ASCT NCT03196414
OX40, CD28 100% 3 6 Mild CP/Flu NCT03455972
  1. BCMA B cell maturation antigen, CAR chimeric antigen receptor, ORR overall response rate, CR complete response, sCR stringent complete response, PR partial response, VGPR very good partial response, CRS cytokine release syndrome, CRES cell related encephalopathy syndrome, Gr grade, DLT dose-limiting toxicity, CP cyclophosphamide, Flu fludarabine, Bu busulphan, ASCT autologous stem cell transplantation